Collaboration supports co-development of RB-340 CAR T cell therapy, application of Refuge’s synthetic biology platform to MD Anderson TIL programs The University of Texas MD Anderson Cancer Center and Refuge Biotechnologies, Inc. today announced a strategic collaboration to advance new cell therapies for potential treatment […]
